# Nilotinib and LDE225 in the Treatment of Chronic or Accelerated Phase Myeloid Leukemia in Patients Who Developed Resistance to Prior Therapy

> **NCT01456676** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 11 (actual)

## Conditions studied

- Philadelphia Chromosome Positive Chronic Myelogenous Leukemia

## Interventions

- **DRUG:** Nilotinib + LDE225

## Key facts

- **NCT ID:** NCT01456676
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01
- **Primary completion:** 2014-02
- **Final completion:** 2014-02
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2020-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01456676

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01456676, "Nilotinib and LDE225 in the Treatment of Chronic or Accelerated Phase Myeloid Leukemia in Patients Who Developed Resistance to Prior Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01456676. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*